Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record.

Pneumococcal macrolide resistance—myth or reality?

Open access
Amsden, Guy W.·1999·Journal of Antimicrobial Chemotherapy

Abstract

Streptococcus pneumoniae is one of the most common community-acquired respiratory tract pathogens, causing as many as ≥20% of all cases of community-acquired pneumonia (CAP) annually. 1 Over the years a number of agents have been utilized as first-line treatment options for this organism. Invariably, as various agents have been used extensively, in-vitro antimicrobial resistance has developed. Penicillin-resistant pneumococci (PRP) have become highly prevalent in many countries over the past 10-15 years and are continuing to spread in many regions of the USA. 2,3,4,5 This (and other) trends in resistance, as well as the recognition of the importance of atypical pathogens, resulted in CAP outpatient treatment guidelines being released in 1993 that recommended that the macrolides be utilized as first-line treatment for patients <60 years of age with no comorbidity. 6 This line of thinking has recently been reinforced by the Infectious Diseases Society of America with their 1998 CAP treatment guidelines. 7 As a result of these recommendations together with, resistance trends, and the advantages of the new azalide azithromycin and the macrolide clarithromycin having antimicrobial activity against all relevant community-acquired respiratory pathogens, these agents have been heavily prescribed over the past few years. 8 As a result of this new prescribing focus, reports are now describing increasing macrolide resistance in pneumococci. 2,3 A study by Doern et al.3 of 1527 isolates of pneumococci recovered from outpatients during the winter months of 1994 and 1995 demonstrated that 10% were resistant by NCCLS standards 9,10 to erythromycin, clarithromycin (≥1.0 mg/L) and azithromycin (≥2.0 mg/L). A separate study by Ballow et al.2 investigated the erythromycin susceptibility of S. pneumoniae, including strains of varying penicillin susceptibilities. The investigators studied 2537 clinical isolates from institutions throughout the USA. Of these, 21% overall were erythromycin resistant. When the isolates with varying penicillin sensitivities were studied, it was demonstrated that the rates of macrolide sensitivity in these strains had also decreased. Isolates with intermediate penicillin susceptibility were only sensitive to erythromycin 63% of the time and only 40% of those with high-level penicillin resistance were erythromycin sensitive. This spread of macrolide resistance, as is the case for other agents, results not only from the appropriate use of these agents but also from inappropriate prescribing habits. 11 It was recently demonstrated by Gonzales et al .,12 that, based on a national survey of ambulatory care physicians, office visits for colds, upper respiratory tract infections and acute bronchitis resulted in 12 million antibiotic prescriptions (accounting for 21% of all antibiotic prescriptions for adults) in 1992. As antibiotics are unnecessary for viral infections and it is becoming commonplace to offer only symptomatic relief to acute bronchitis patients, this report represents massive over-prescribing in the clinical setting. Curtailment of erythromycin over-prescribing has been demonstrated recently in Finland to decrease macrolide resistance in Group A streptococci. 13 Curiously, although this drop in resistance coincided with a decrease in erythromycin use there was an increase in use of azithromycin and the other macrolides clarithromycin and roxithromycin. This observation could, therefore, possibly result from poor compliance with erythromycin and better compliance with the newer agents, resulting in more effective eradication of the organisms, rather than encouraging resistance. 14 As a result of these in-vitro reports, many prescribers are changing their choice of antibiotics for pneumococcal, as well as for community-acquired respiratory tract infections in general, away from macrolides. However, the practice of just changing one drug for another without also altering poor prescribing habits merely results in different resistance issues. Despite this trend of decreased macrolide use, the question that still needs to be addressed is whether these alarming in-vitro results correlate with a negative impact on clinical efficacy in vivo. There has always been controversy concerning the relevance of laboratory sensitivity standards in the clinical setting without taking into consideration both the pharmacokinetics and pharmacodynamics of the drug in vitro. An example of this would be the NCCLS guidelines indicating that a strain of Pseudomonas aeruginosa with a gentamicin MIC of 4 mg/L should be considered sensitive. 9,10 Clinically, owing to the need to provide a peak serum concentration to MIC ratio of at least 10:1 for aminoglycosides, target peak serum gentamicin concentrations would have to be at least 40 mg/L, which is not realistic (and perhaps not safe) even with od dosing schemes. 15 Pneumococcal macrolide resistance manifests itself through mechanisms classified within MLS resistance, s

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/44.1.1

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 169

Metadata

Authors
Amsden, G. W.
Venue
Journal of Antimicrobial Chemotherapy
Published
1999-07
Volume
44
Issue
1
Pages
1-6
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W2158583961
Cited by
169
References
0
FWCI
13.52
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pneumococcal macrolide resistance—myth or reality? https://app.cochat.ai/papers/10.1093/jac/44.1.1
The paper
Amsden, G. W. (1999). Pneumococcal macrolide resistance—myth or reality? Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/44.1.1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.